Grant ID DP220066
Awarded On August 17, 2022
Title Enhancing Cancer Treatment through Direct, Localized, and Sustained Delivery of Therapeutic Agents: Clinical Evaluation in Locally Advanced Pancreatic Cancer
Program Product Development Research
Award Mechanism Company Relocation
Institution/Organization PanTher Therapeutics, Inc
Principal Investigator/Program Director Laura Indolfi
Cancer Sites Pancreas
Contracted Amount $14,268,315*

*Pending contract negotiation

Lay Summary

Pancreatic cancer is a highly lethal disease and the third leading cause of cancer death. The only chance for cure remains complete surgical removal, but this is impossible for most patients due to advanced local growth or metastatic spread. For inoperable patients, multiple approaches have been attempted to shrink tumor and allow for subsequent resection. Multiagent chemotherapy is utilized in this "neoadjuvant" approach but has met with limited success due to modest activity and significant side effects. By directly targeting tumors, PanTher's novel approach looks to significantly increase drug accumulation at the site, while dramatically reducing systemic side effects to improve antitumor...

Read More